Biocon Revenues
Syngene International Q3 results: PAT rises 17.6%, revenue up 10.6%
During the quarter, Discovery Services launched "China+1" pilots with large and mid-size pharma companies and converted them into long-term contracts. Growth signals stabilizing
 "Syngene International Q3 results: PAT rises 17.6%, revenue up 10.6%")
Biocon considers selling generic API biz; turn into biosimilar major
The generic API business has been one of the primary businesses for Biocon, however, in recent years, the segment's contribution towards the company's consolidated financials has declined
 "Biocon considers selling generic API biz; turn into biosimilar major")
Biocon Biologics targets top three biosimilar spot: Shreehas Tambe
The opportunity ahead of us is massive because over the next 10 odd years until 2032, we see 55 blockbuster molecules and biologics going out or losing exclusivity, says Tambe
 "Biocon Biologics targets top three biosimilar spot: Shreehas Tambe")
Biocon Q2 results: Net profit zooms over two-fold to Rs 173 crore
Biotechnology major Biocon on Friday said its consolidated net profit rose an over two-fold to Rs 173 crore for the second quarter ended September 30, 2023. The company had reported a net profit of Rs 82 crore for the July-September period of the last fiscal. Total income rose to Rs 3,620 crore for the second quarter as against Rs 2,384 crore in the year-ago period, Biocon Ltd said in a regulatory filing. Shares of the company on Friday ended 0.11 per cent higher at Rs 227.35 apiece on the BSE.
 "Biocon Q2 results: Net profit zooms over two-fold to Rs 173 crore")
Biocon Biologics gets positive opinion from EMA for ophthalmology product
Yesafili aims to treat various visual impairments and age-related macular degeneration
Biocon Q2 results: Net profit declines 10% to Rs 168 crore, revenue up 26%
Biocon's core Ebitda came in at Rs 816 crore, up 34 per cent
Q4 a minor blip in Biocon's growth story, recovery expected in Q1FY21
Analysts estimate 38 per cent annual growth in earnings during FY20-22
 "Q4 a minor blip in Biocon's growth story, recovery expected in Q1FY21")
Top headlines: Biz sentiment sinks to record low, Moody's outlook on banks
Business Standard brings to you the top headlines of the day
 "Top headlines: Biz sentiment sinks to record low, Moody's outlook on banks")
Biocon targets $1 bn in revenues by FY19 with new products and services
The Bengaluru-based firm has been chasing the target since 2011
